Page last updated: 2024-09-03

vadimezan and carboplatin

vadimezan has been researched along with carboplatin in 6 studies

Compound Research Comparison

Studies
(vadimezan)
Trials
(vadimezan)
Recent Studies (post-2010)
(vadimezan)
Studies
(carboplatin)
Trials
(carboplatin)
Recent Studies (post-2010) (carboplatin)
2721610112,8954,0015,244

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR1
Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J1
Freitag, L; Gibbs, D; Jameson, MB; Mainwaring, PN; McKeage, MJ; Reck, M; Rosenthal, MA; Sullivan, R; Von Pawel, J1
Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N1
Albert, I; Douillard, JY; Fan, X; Fandi, A; Heo, DS; Lara, PN; Losonczy, G; McKeage, MJ; Nakagawa, K; Reck, M; Scagliotti, G; von Pawel, J1
Cathomas, R; Erdmann, A; Früh, M; Fustier, P; Krasniqi, F; Küttel, E; Mamot, C; Pless, M; Rauch, D; Siano, M; Simcock, M; Tscherry, G; Zippelius, A1

Trials

5 trial(s) available for vadimezan and carboplatin

ArticleYear
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    British journal of cancer, 2008, Dec-16, Volume: 99, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones

2008
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Xanthones

2009
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
    Cancer science, 2011, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones

2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Failure; Xanthones

2011
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
    Clinical lung cancer, 2013, Volume: 14, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome; Xanthones

2013

Other Studies

1 other study(ies) available for vadimezan and carboplatin

ArticleYear
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones

2003